Donegan Michael C
- SEC CIK
- 0001627810
No open-market purchases or sales filed in the past year.
Current role at each company
- TXMD TherapeuticsMD, Inc.Prin. Fin. and Acctg. Officeras of Apr 14, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Donegan Michael C as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 2, 2021 (view filing) | Nov 30 | 2 days | Donegan Michael CCAO and VP of Finance | SSale | −29.8K | $0.54 | −$16.1K | −23.1%99.4K after | |
| Dec 9, 2022 (view filing) | Dec 6 | 3 daysLate | Donegan Michael CInterim CFO/CAO/VP of Finance | SSale | −910 | $4.78 | −$4.35K | −16.7%4.55K after | |
| Jan 25, 2023 (view filing) | Jan 23-24 | 2 days | Donegan Michael CPrin. Fin. and Acctg. Officer | SSale | −1.31K | $5.34 | −$6.99K | −14.7%7.61K after | 2 lots |
| Jan 30, 2023 (view filing) | Jan 26-27 | 4 days | Donegan Michael CPrin. Fin. and Acctg. Officer | SSale | −1.70K | $5.08 | −$8.62K | −12.5%11.9K after | 2 lots |